HCPCS Level II code J1456 represents an injectable formulation of fosaprepitant (Teva), billed per 1 mg unit and specified as not therapeutically equivalent to J1453. This drug is used as a neurokinin-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting (CINV) and is typically administered via infusion in outpatient infusion centers, hospital outpatient departments, or physician offices. Nationally, accurate coding for branded and non-equivalent formulations matters for drug inventory management, billing integrity, and payer coverage determinations.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, billing considerations tied to unit-based drug J-codes, and what to expect regarding common sites of service. The publication highlights benchmarks and policy-relevant topics such as payer coverage patterns, billing unit interpretation, and potential implications where a product is explicitly not therapeutically equivalent to another HCPCS drug code. Where specific payer policies, modifiers, taxonomies, ICD-10 crosswalks, or utilization benchmarks are needed, the input data is limited — readers are directed to payer policy manuals and drug labeling for operational decisions.

This summary is nationally focused and intended for billing managers, revenue cycle professionals, and clinicians involved in oncology supportive care coding and reimbursement.